China
Wins in court have been key to the six-year-old firm’s growth, as one of its founders explains
Loke Khoon Tan and Stephanie Yip at Dentons explain what brand owners need to know ahead of January 1 2027, when updates to China’s Trade Mark Law come into force
New US bills signal that firms should work with clients to ensure they are complying with potential regulatory requirements
Nick Redfearn, head of enforcement at Rouse and a classic car enthusiast, explains the sudden viral appearance of classic car restomod parts from China and the impact of IP in this new trade
Sponsored
Sponsored
-
Sponsored by CCPIT Patent and Trademark Law OfficeJi Liu and Shaohui Yuan of CCPIT Patent and Trademark Law Office explain how China balances intellectual property protection and the prevention of monopolistic behaviour, using two significant cases to demonstrate the key points -
Sponsored by Wanhuida Intellectual PropertyZhigang Zhu, Xiaoyang Yang, and Feng Zheng of Wanhuida Intellectual Property outline the intellectual property-related challenges Chinese enterprises face in pursuing growth through overseas expansion, and explain the steps that can help navigate the complexities
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Chenxi Cui of Tahota Law Firm draw on the case and several other legal disputes to explore the fractious relationship between games console emulators and manufacturers
-
Sponsored by Liu Shen & AssociatesJun Qiu of Liu, Shen & Associates analyses two recent CNIPA decisions that provide insights into the application of the good faith principle in patent re-examination and invalidation procedures in China
-
Sponsored by Liu Shen & AssociatesDongguo Liang of Liu, Shen & Associates says DeepSeek should take swift action to address ‘insufficient planning’ in its intellectual property protection strategy and an ‘underdeveloped’ patent portfolio
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
